New targets at AACR, biopharma deals, Kurma fund — a BioCentury podcast 

Target discovery, pan-RAS ADCs at the American Association for Cancer Research

More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates.

The analysts also discuss the latest deal by Eli Lilly and Co. (NYSE:LLY) — for a JAK-2 inhibitor from Ajax Therapeutics Inc. — and what the current pace of M&A and partnerships says about the state of biopharma dealmaking. This episode also features Kurma Partners’ new venture fund and the latest in BioCentury’s Emerging Company Profile series, spotlighting U.K.-based rheumatoid arthritis company  Elevara Medicines Ltd.

This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.